CDXS
Price
$2.86
Change
-$0.07 (-2.39%)
Updated
Aug 6, 04:59 PM (EDT)
Capitalization
242.74M
7 days until earnings call
DNLI
Price
$14.35
Change
+$0.06 (+0.42%)
Updated
Aug 6, 04:59 PM (EDT)
Capitalization
2.08B
85 days until earnings call
Interact to see
Advertisement

CDXS vs DNLI

Header iconCDXS vs DNLI Comparison
Open Charts CDXS vs DNLIBanner chart's image
Codexis
Price$2.86
Change-$0.07 (-2.39%)
Volume$12.9K
Capitalization242.74M
Denali Therapeutics
Price$14.35
Change+$0.06 (+0.42%)
Volume$12.25K
Capitalization2.08B
CDXS vs DNLI Comparison Chart in %
Loading...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDXS vs. DNLI commentary
Aug 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDXS is a StrongBuy and DNLI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 07, 2025
Stock price -- (CDXS: $2.93 vs. DNLI: $14.29)
Brand notoriety: CDXS and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDXS: 122% vs. DNLI: 126%
Market capitalization -- CDXS: $242.74M vs. DNLI: $2.08B
CDXS [@Biotechnology] is valued at $242.74M. DNLI’s [@Biotechnology] market capitalization is $2.08B. The market cap for tickers in the [@Biotechnology] industry ranges from $215.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.33B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDXS’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • CDXS’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, CDXS is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDXS’s TA Score shows that 4 TA indicator(s) are bullish while DNLI’s TA Score has 5 bullish TA indicator(s).

  • CDXS’s TA Score: 4 bullish, 5 bearish.
  • DNLI’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than CDXS.

Price Growth

CDXS (@Biotechnology) experienced а +3.90% price change this week, while DNLI (@Biotechnology) price change was +5.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.67%. For the same industry, the average monthly price growth was +14.79%, and the average quarterly price growth was +13.41%.

Reported Earning Dates

CDXS is expected to report earnings on Oct 30, 2025.

DNLI is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (-0.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.08B) has a higher market cap than CDXS($243M). DNLI YTD gains are higher at: -29.882 vs. CDXS (-38.574). CDXS has higher annual earnings (EBITDA): -62.28M vs. DNLI (-505.16M). DNLI has more cash in the bank: 818M vs. CDXS (59.8M). DNLI has less debt than CDXS: DNLI (48.6M) vs CDXS (59.5M). CDXS has higher revenues than DNLI: CDXS (49.8M) vs DNLI (0).
CDXSDNLICDXS / DNLI
Capitalization243M2.08B12%
EBITDA-62.28M-505.16M12%
Gain YTD-38.574-29.882129%
P/E RatioN/AN/A-
Revenue49.8M0-
Total Cash59.8M818M7%
Total Debt59.5M48.6M122%
FUNDAMENTALS RATINGS
CDXS vs DNLI: Fundamental Ratings
CDXS
DNLI
OUTLOOK RATING
1..100
7066
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
93
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
5783
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
n/a35

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CDXS's Valuation (48) in the Chemicals Specialty industry is somewhat better than the same rating for DNLI (93) in the Biotechnology industry. This means that CDXS’s stock grew somewhat faster than DNLI’s over the last 12 months.

CDXS's Profit vs Risk Rating (100) in the Chemicals Specialty industry is in the same range as DNLI (100) in the Biotechnology industry. This means that CDXS’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (97) in the Biotechnology industry is in the same range as CDXS (99) in the Chemicals Specialty industry. This means that DNLI’s stock grew similarly to CDXS’s over the last 12 months.

CDXS's Price Growth Rating (57) in the Chemicals Specialty industry is in the same range as DNLI (83) in the Biotechnology industry. This means that CDXS’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (99) in the Biotechnology industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that DNLI’s stock grew similarly to CDXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDXSDNLI
RSI
ODDS (%)
Bearish Trend 2 days ago
75%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 7 days ago
77%
Declines
ODDS (%)
Bearish Trend 7 days ago
84%
Bearish Trend 9 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ANDRX16.340.02
+0.12%
AQR International Defensive Style R6
OBCHX8.67N/A
N/A
Oberweis China Opportunities
DGLCX18.64N/A
N/A
BNY Mellon Global Stock - C
BTMGX18.19N/A
N/A
iShares MSCI EAFE Intl Idx G
BGIVX15.71-0.01
-0.07%
Baillie Gifford International Alpha 5